{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:51Z","timestamp":1787027031615,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    Medication-related osteonecrosis of the jaw (MRONJ) is an oral complication in cancer patients being treated with either antiresorptives, mainly denosumab and bisphosphonates, or antiangiogenic drugs. Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) for the treatment of patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC). TKI-induced osteonecrosis of the jaw has been reported in recent years, but these cases almost occur in combination with bisphosphonates, and the data on MRONJ associated to osimertinib is scarce.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Case report:<\/jats:bold>\n                    We reported a case of MRONJ associated only with osimertinib. A 69-year-old female patient with NSCLC developed MRONJ after 4\u00a0years of treatment with osimertinib. Six months ago, she felt persistent pain and swelling in the right maxilla. After 3\u00a0months of pain, her dentist extracted one tooth in the right maxilla under local anesthesia. We examined her gingiva and found fistula and pus spillage. A digital volume tomography scan revealed sequestrum. The patient underwent surgical debridement of the necrotic bone under general anesthesia and administered intravenous antibiotics at the hospital. Histopathological analysis of the bone biopsy revealed a diagnosis of MRONJ.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This report provides evidence that osimertinib monotherapy can cause MRNOJ, and has a contribution to explore the formation mechanism of MRONJ. For those patients who take osimertinib, routine oral examinations and monitoring should be performed before and during treatment, as well as prompt closure of wounds and antibiotic treatment to avoid infection after invasive oral surgery such as tooth extraction.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.947947","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T01:11:30Z","timestamp":1660093890000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Osimertinib: Another medication related to osteonecrosis of the jaws? A case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Feng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrm2183","article-title":"Molecular regulation of angiogenesis and lymphangiogenesis","volume":"8","author":"Adams","year":"2007","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e6944","DOI":"10.7759\/cureus.6944","article-title":"Medication-related osteonecrosis of the jaw: A review","volume":"12","author":"AlDhalaan","year":"2020","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.sbi.2014.10.002","article-title":"Putting together structures of epidermal growth factor receptors","volume":"29","author":"Bessman","year":"2014","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000313680","article-title":"Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib","volume":"33","author":"Bozas","year":"2010","journal-title":"Onkologie"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.1016\/s0021-9258(19)38983-5","article-title":"Epidermal growth factor","volume":"265","author":"Carpenter","year":"1990","journal-title":"J. Biol. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"B7","first-page":"273","article-title":"Analysis of mammalian fibroblast transformation by normal and mutated human EGF receptors","volume":"4","author":"Haley","year":"1989","journal-title":"Oncogene"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s00198-017-4063-7","article-title":"A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: Can primary wound closure and a drug holiday really prevent MRONJ?","volume":"28","author":"Hasegawa","year":"2017","journal-title":"Osteoporos. Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41368-020-00093-2","article-title":"Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw","volume":"12","author":"He","year":"2020","journal-title":"Int. J. Oral Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: Presentation of three cases","volume":"110","author":"Hoefert","year":"2010","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1517\/14728222.2010.511617","article-title":"HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer","volume":"14","author":"Jackson","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"B12","first-page":"2507","article-title":"Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue","volume":"3","author":"Joseph","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Min. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pharmthera.2011.03.012","article-title":"Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis","volume":"131","author":"Larsen","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.7150\/jca.29933","article-title":"Cytochalasin H inhibits angiogenesis via the suppression of HIF-1\u03b1 protein accumulation and VEGF expression through PI3K\/AKT\/P70S6K and ERK1\/2 signaling pathways in non-small cell lung cancer cells","volume":"10","author":"Ma","year":"2019","journal-title":"J. Cancer"},{"key":"B17","first-page":"455","article-title":"Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Rom. J. Morphol. Embryol."},{"key":"B18","first-page":"29","article-title":"Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib-a case report with clinical implications","volume":"4","author":"Nicolatou-Galitis","year":"2013","journal-title":"Forum Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/sj.onc.1205260","article-title":"Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"key":"B20","first-page":"276","article-title":"Vascular permeability factor gene expression in normal and neoplastic human ovaries","volume":"54","author":"Olson","year":"1994","journal-title":"Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/medicina57050463","article-title":"Infection as an important factor in medication-related osteonecrosis of the jaw (MRONJ)","volume":"57","author":"Otto","year":"2021","journal-title":"Med. Kaunas."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1158\/0008-5472.CAN-05-3090","article-title":"EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms","volume":"66","author":"Pore","year":"2006","journal-title":"Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/107327480200902S05","article-title":"Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers","volume":"9","author":"Rosen","year":"2002","journal-title":"Cancer control"},{"key":"B24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update","volume":"35","author":"Ruggiero","year":"2009","journal-title":"Aust. Endod. J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"B26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.joms.2009.10.026","article-title":"Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction","volume":"68","author":"Saia","year":"2010","journal-title":"J. Oral Maxillofac. Surg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"Doc03","DOI":"10.3205\/iprs000153","article-title":"Tocilizumab: Another medication related to osteonecrosis of the jaws? A case report and literature review","volume":"10","author":"Sakkas","year":"2021","journal-title":"GMS Interdiscip. Plast. Reconstr. Surg. DGPW"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000320006","article-title":"Mechanisms of ocular angiogenesis and its molecular mediators","volume":"46","author":"Siemerink","year":"2010","journal-title":"Dev. Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/ijc.32399","article-title":"Osimertinib and jaw osteonecrosis? A case report","volume":"145","author":"Subramanian","year":"2019","journal-title":"Int. J. Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1038\/onc.2010.16","article-title":"Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells","volume":"29","author":"Xu","year":"2010","journal-title":"Oncogene"},{"key":"B31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ijc.32097","article-title":"Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis","volume":"145","author":"Yi","year":"2019","journal-title":"Int. J. Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"E1236","DOI":"10.3390\/molecules21091236","article-title":"Osimertinib (AZD9291), a mutant-selective EGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells","volume":"21","author":"Zhang","year":"2016","journal-title":"Molecules"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.947947\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T01:11:39Z","timestamp":1660093899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.947947\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":32,"alternative-id":["10.3389\/fphar.2022.947947"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.947947","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"article-number":"947947"}}